Descriptive analysis of practice and postoperative outcomes of patients with a final histological diagnosis of oncocytoma included in The British Association of Urological Surgeons (BAUS) nephrectomy registry from 01/01/2013 to 31/12/2016. Short-term outcomes were assessed over a follow-up of 60 days.
Introduction
Increasing use of imaging has led to a rise in the diagnosis of renal lesions in general, and of small renal masses (SRMs; <4 cm of greater axis) in particular [1] . The classic diagnostic and treatment pathway of renal masses typically involves contrast-enhanced imaging followed by surgery, usually either in the form of partial (PN) or radical nephrectomy (RN) [2] . Whilst imaging can be helpful in recognising some benign lesions, such as classic fat-containing angiomyolipomas, the diagnostic accuracy between oncocytomas and RCC is generally poor [3] .
Oncocytomas arise from the distal tubular epithelium of the kidney. Even when associated with typical features of aggressiveness, such as large size, perinephric fat and vascular invasion, they display non-malignant behaviour and have an excellent prognosis [4, 5] . Renal tumour biopsy can be used to ascertain the histological nature of SRMs and guide management but has yet to be adopted into standard clinical practice. Reflecting this, oncocytoma is a postoperative diagnosis in 3-4% of PNs and RNs [5] . A previous analysis of the BAUS nephrectomy registry has shown that, in the UK, 3.9% of surgeries for both benign and malignant renal tumours are associated with major complications [6] .
However, given its benign nature, surgery may represent overtreatment in small asymptomatic renal oncocytomas.
In the present study, using data from a nationwide surgical registry, we aimed to assess the contemporary UK surgical experience with renal oncocytomas, and evaluate the postoperative short-term outcomes associated with this benign tumour.
Patients and Methods
In England, urological surgeons have been mandated to report on all nephrectomy cases to the BAUS registry (www.baus.org.uk/patients/surgical_outcomes) since December 2012. Surgeons from Scotland, Wales, and Ireland can also input data but this was not mandated in the time period studied. The BAUS surgical registry has ethical approval under Section 251 of the NHS Act 2006.
We audited this registry for all patients with a final diagnosis of renal oncocytoma from 01/01/2013 to 31/12/2016 and sought to assess clinical practice and outcomes over a followup period of 60 days. Long-term outcomes were not analysed due to the high rate of underreporting (not reported for 83.4% of cases).
Data items included demographic characteristics, comorbidity index (using Charlson index, age-related Charlson index, and American Society of Anesthesiologists [ASA] grading systems), performance status (using the WHO performance status classification), pathological tumour staging (according to the 2010 TNM staging classification), use of preoperative biopsy, type of surgery, surgical approach, and operative complications.
All complications were categorised and predefined in the registry, and surgeons reporting to the database chose the most appropriate options. More than one complication could be reported for each patient. In addition to formal report of intraoperative bleeding, the event was also considered present if both of the following conditions were met: there was blood loss of >1 L during surgery and the transfusion of packed red blood cells was required intraoperatively. Postoperative bleeding was defined solely by the surgeon's report of occurrence of a postoperative bleeding event. Baseline renal function was considered normal if the estimated GFR (eGFR; calculated using the Modification of diet in renal disease [MDRD] study equation) was ≥60 mL/min/1.73 m 2 or, when eGFR was missing, if serum creatinine levels were <110 lmol/L. Postoperative eGFR was recorded as a categorical variable in the registry ('normal' as >60 mL/min/ 1.73 m 2 or 'abnormal' as <60 mL/min/1.73 m 2 ). In addition to formal report by the surgeon of postoperative renal impairment as a complication, the event was also considered if an eGFR of <60 mL/min/1.73 m 2 was recorded postoperatively in a patient who had normal baseline renal function preoperatively.
Patients who had in-hospital operative complications were attributed a Clavien-Dindo classification grade by the data reporting surgeon (the highest graded complication was considered for analysis). Events graded ≥III were considered major complications. Where an unplanned intensive care unit admission had taken place, cases were re-graded as a major complication (grade IV) if the Clavien-Dindo classification grade was missing (four cases) or a grade of I or II had been attributed (four cases). Finally, mortality was also recorded and incorporated any deaths occurring during or after admission within the first 60 days after surgery.
Descriptive analysis of all data was performed using Microsoft Excel. Continuous variables are presented as median, range, and interquartile range (IQR). Categorical variables are presented as absolute number, and relative proportion of cases (%). When relevant, missing data were presented as absolute numbers, and relative proportions of cases (%).
The BAUS funds data management of the BAUS registry database. No specific funding was allocated to conduct the present study. The 1202 cases of oncocytoma were operated in 136 centres: the median (IQR; range) number of cases per centre was 5 (9.25; 1-49). Most patients were male (756 patients; 62.9%), with a median (IQR; range) age of 68 (13; 25-100) years (Table 1) . Only two patients (0.2%) had confirmed hereditary syndromes (one case of tuberous sclerosis and one of BirtHogg-Dub e syndrome) and 16 (1.3%) patients had bilateral renal lesions. Most patients were asymptomatic (860 patients; 71.5%) and had normal baseline renal function (797; 66.3%). The median (IQR; range) tumour size was 4.1 (3; 1-25) cm, and most lesions were ≤7 cm (887 patients; 73.8%).
Results

During
Of 1202 oncocytoma cases, 35 patients had preoperative renal tumour biopsy (2.9%): eight biopsies occurred in 2013, seven in 2014, seven in 2015, and 13 in 2016. Of biopsied patients, the median (IQR; range) renal mass size was 3.8 (2.3; 1.5-8.5) cm. Over half had benign histology on biopsy (18 patients; 51.4%) but seven (20%) were reported malignant on histology, eight (22.9%) biopsies were non-diagnostic, and in two cases (5.7%) biopsy histology was missing ( 
176 (14.6) *Symptoms were reported in 300 cases but up to four symptoms were reported per case, with a total of 465 symptoms reported. patients were diagnosed after PN (65.6%), 163 after RN (31.2%), and 17 after other non-nephron-sparing approaches (3.2%).
The conversion rate from all minimally invasive techniques to open surgery was 3.4% (32 patients). After surgery, the median (IQR; range) length of hospital stay was 4 (3; 0-99) days.
Overall, one in five patients had in-hospital complications (243 patients; 20.2%). These included 31 (12.8%) patients with intraoperative complications, 195 (80.2%) with postoperative complications, and 17 (7%) patients with both intra-and postoperative complications. The most frequent intraoperative complication was bleeding (35 patients), followed by pneumothorax (three), splenectomy (two), bowel injury (one), liver injury (one); seven intraoperative complications were classified as 'other' (of note, one patient developed more than one intraoperative complication). The most frequent postoperative complication was renal impairment (57 patients, representing 6.4% of all patients with reported normal baseline renal function), followed by chest infection (37), bleeding (27), ileus (20), wound infection (23), problematic pain control (two), and deep vein thrombosis/pulmonary embolus (one); in 60 patients postoperative complications were classified as 'other', and in three they were not classified (of note, 15 patients developed more than one postoperative complication). In total, 123 patients (10.2%) were admitted to an intensive care unit after surgery: 104 (84.6%) admissions were planned but 17 (13.8%) were unplanned (data was missing for two patients).
Clavien-Dindo classification grades were attributed to 168 patients (69.1% of all patients with complications), 48 of which were considered major complications (representing 4% of the whole cohort). Of all patients with complications, 46 were classified as Clavien-Dindo grade I, 74 as grade II, 16 as grade IIIa, 17 as grade IIIb, 12 as grade IVa/b, and three as grade V.
Apart from the three in-hospital deaths, one additional death occurred within 30 days of surgery and another within 60 days of surgery, resulting in a 30-day mortality rate of 0.3% and a 60-day mortality rate of 0.4%. All five deaths occurred in male patients aged >65 years. One patient had a lesion of <4 cm (3.8 cm) and two had lesions between 4 and 7 cm (4.4 and 6.1 cm). Two patients had an ASA grade of III. The cause of death (acute pancreatitis after surgery for a left-sided renal tumour and bowel ischaemia that required resection after an open RN) was only detailed for two patients that died during hospital admission.
Discussion
We report on the largest published surgical series of renal oncocytomas. Our present analysis shows that, in the UK, a significant number of patients with this benign kidney tumour are currently diagnosed after surgery. Nearly half (49.2%) of patients operated on had SRMs and 73.8% were tumours of <7 cm. Moreover, one in five patients had inhospital operative complications, most commonly bleeding and renal impairment. Importantly, 4% of the cohort had major complications and five deaths occurred within 60 days of surgery.
The present study has a number of limitations: its observational nature, possible under or misreporting, lack of central pathology review, and short-follow up. Likewise, the registry does not capture lesions on surveillance or ablated after biopsy, so the true incidence of oncocytomas and outcomes of other management options cannot be extrapolated. Still, we believe that the study results warrant some reflection on current practices.
Renal oncocytomas are typically non-aggressive tumours, and the risk of treatment complications, which are justifiable in the context of malignancy or symptom control, may be less acceptable with a benign asymptomatic tumour. The frequency of oncocytomas in the overall registry (3.7%) and the short-term complication rate of this surgical cohort were similar to previous publications encompassing both benign and malignant surgical cases [5, 6] . In the UK, previous analysis of the BAUS registry has shown that 3.9% of patients who had surgery for benign or malignant kidney tumours had major operative complications [6] . A risk of this magnitude may be acceptable considering the potential mortality of localised kidney cancer (5-year relative survival rate of~80% for stage I and II disease [7] ), but may be questionable in the context of benign disease. To our knowledge, not a single disease-specific death has been reported in the literature for patients with renal oncocytomas. In the present cohort, surgery led to the death of five patients. Moreover, in the present analysis possible underreporting and the lack of long-term follow-up may have contributed towards underestimation of the total complication burden. We observed that >70% of patients in the present cohort were asymptomatic and nearly half presented with SRMs. At least 18% had preoperative renal dysfunction and almost half were aged ≥70 years. Thus, surgery likely represented overtreatment for a significant proportion of the cohort and a preoperative diagnosis of a benign tumour might have led to a more informed consultation and consent process.
The BAUS registry reports only surgical cases, so the number of patients undergoing preoperative biopsy must not be interpreted as an estimate of total UK utilisation of renal tumour biopsy. However, considering the high number of small renal tumours in the present series, we suspect tumour biopsy is still underutilised in the UK. Likewise, the fact that only half of cases with a preoperative biopsy were correctly categorised should not be interpreted as the nationwide biopsy diagnostic accuracy. These data are skewed by the fact 896 © 2018 The Authors BJU International © 2018 BJU International that they were captured on a surgical registry. If patients who had a biopsy diagnosis of an oncocytoma were offered other management options instead of surgery, we would expect that the preoperative biopsies captured in any surgical registry to be almost all malignant, non-diagnostic or inconclusive. A systematic review of large-volume centre series has reported a median diagnostic accuracy rate of 90.3% for renal tumour biopsy [8] . Thus, in centralised care a high diagnostic rate can be achieved and using this strategy could help prevent overtreatment-associated morbidity.
European guidelines advise that renal oncocytomas can be managed with active surveillance, if histological diagnosis has been attained [2] . Studies performed in high-volume tertiary referral centres have shown that renal tumour biopsy is an accurate and safe procedure [8, 9] : bleeding that requires transfusion or intervention is rare (<1%) and the fear of tumour seeding is unfounded with the use of coaxial needles. However, due to shared morphological features between oncocytoma and chromophobe RCC, the distinction between both on biopsy can be challenging. In a recent systematic review, including 10 renal tumour biopsy series, a quarter of 46 cases initially diagnosed as oncocytic tumours on biopsy were found to be RCC after surgery [10] . Nonetheless, equivocal biopsies were not distinguished from cases with more definitely benign features. Moreover, from the aggregated analysis of 205 biopsy cases, only 46 proceeded to surgery: selection bias of dubious cases towards surgery rather than other management strategies could have influenced results. A large single-centre series (144 biopsied oncocytic tumours), not included in the above cited systematic review, suggests and uses morphological features and expression markers that can aid in the distinction between oncocytoma and malignancy on biopsy [11] . Using these tools, out of 28 cases that underwent resection, concordance between biopsy and final histology was 94%, with only one oncocytoma in six on biopsy being reclassified as possible low-grade RCC after surgery [11] . Studies that have reported on the diagnostic rate and accuracy of renal tumour biopsy stem from large expert centres. Additionally, in the present cohort a considerable number of patients were deemed to have a malignant mass at biopsy that later was confirmed to be an oncocytoma. Thus, the widespread adoption of renal tumour biopsy for the preoperative diagnosis of oncocytoma may only be applicable if accompanied by centralisation of services and histology review by specialist uro-pathologists. Finally, once validated, alternative diagnostic methods with high specificity, e.g. multi-parametric MRI and/or 99 m Tc-sestamibi single-photon emission CT (SPECT)/CT, could potentially be used to further elucidate any diagnostic uncertainties [12, 13] .
Currently in the UK there is only a mandatory surgical registry. Thus, the proportion of oncocytoma cases on active surveillance or subject to other management methods remains unknown. Active surveillance is a safe management option for T1 oncocytomas and chromophobe RCCs [14, 15] . Moreover, tumour ablation has been shown to be more costeffective and safer than surgery for SRMs [16] and could be an attractive alternative treatment option for histologically confirmed symptomatic oncocytomas or for oncocytic tumours with hybrid features.
Similar to other health systems, the direction of policy change in the UK is towards far greater centralisation for the evaluation and management of renal masses. With such centralisation, it may be feasible to set critical mass among interventional radiology and pathology, enabling an increased and accurate use of tumour biopsy for SRMs. This will also aid the development of translational and clinical research to predict more accurately the subtype in equivocal cases, the study of the natural course of disease, and in the establishment of active surveillance and ablation registries. Increased utilisation of renal tumour biopsy in the kidney mass diagnostic pathway will allow a more informed consultation and empower patients and clinicians. This will enable reduction in the overtreatment of benign lesions, thus improving clinical outcomes, and redirect efforts and costs towards potentially life-threatening malignancies.
To conclude, the complication burden associated with surgical removal of renal oncocytoma in the UK is not negligible. Treatment morbidity is significant in the context of a benign indolent tumour. Histology disclosure by increased use of renal tumour biopsy at diagnosis can redirect patients with renal oncocytomas and other benign tumours to other less morbid and less costly management options, including active surveillance or ablation.
